+

WO2008133129A1 - Therapeutic agent for glaucoma comprising adenosine a2a receptor agonist as active ingredient - Google Patents

Therapeutic agent for glaucoma comprising adenosine a2a receptor agonist as active ingredient Download PDF

Info

Publication number
WO2008133129A1
WO2008133129A1 PCT/JP2008/057394 JP2008057394W WO2008133129A1 WO 2008133129 A1 WO2008133129 A1 WO 2008133129A1 JP 2008057394 W JP2008057394 W JP 2008057394W WO 2008133129 A1 WO2008133129 A1 WO 2008133129A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
ring
glaucoma
adenosine
therapeutic agent
Prior art date
Application number
PCT/JP2008/057394
Other languages
French (fr)
Japanese (ja)
Inventor
Atsushi Shimazaki
Noriko Kawabata
Tomoko Kirihara
Original Assignee
Santen Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co., Ltd. filed Critical Santen Pharmaceutical Co., Ltd.
Publication of WO2008133129A1 publication Critical patent/WO2008133129A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals
    • C07H19/167Purine radicals with ribosyl as the saccharide radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

GW-328267, UK-432097, or a compound represented by the general formula (1) or a salt thereof, which is an adenosine A2A receptor agonist, exhibits an excellent ocular hypotensive effect in the test on decrease in ocular tension, and is therefore useful as a prophylactic or therapeutic agent for glaucoma or ocular hypertension. In the general formula, W represents a hydrogen atom or a group represented by the general formula (8); the ring A represents a benzene ring, a pyridine ring, a pyrazole ring, an imidazole ring, a cyclohexane ring or the like; X represents a single bond, O-CH2-CH2, NH-NH=CH, NH-CH2-CH2, CO-NH-CH2 or the like; Y represents CH or N; Z represents CH2 or O; R1 represents a hydrogen atom, a halogen atom, an alkyl group, an alkylaminocarbonyl group or the like; R2 represents a hydroxyalkyl group, an alkylamino group, an alkylaminocarbonyl group, a triazolyl group or the like; and R3 represents a hydrogen atom, an alkyl group or the like.
PCT/JP2008/057394 2007-04-16 2008-04-16 Therapeutic agent for glaucoma comprising adenosine a2a receptor agonist as active ingredient WO2008133129A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-106917 2007-04-16
JP2007106917 2007-04-16

Publications (1)

Publication Number Publication Date
WO2008133129A1 true WO2008133129A1 (en) 2008-11-06

Family

ID=39925585

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/057394 WO2008133129A1 (en) 2007-04-16 2008-04-16 Therapeutic agent for glaucoma comprising adenosine a2a receptor agonist as active ingredient

Country Status (2)

Country Link
JP (1) JP2008285478A (en)
WO (1) WO2008133129A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010524933A (en) * 2007-04-16 2010-07-22 参天製薬株式会社 Glaucoma therapeutic agent containing an adenosine derivative as an active ingredient

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020253866A1 (en) * 2019-06-21 2020-12-24 中国人民解放军军事科学院军事医学研究院 Adenosine compound, pharmaceutically acceptable salt or stereoisomeride thereof, and use

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06128281A (en) * 1992-04-24 1994-05-10 Whitby Res Inc Hydrazoadenosines
WO2000012098A1 (en) * 1998-09-01 2000-03-09 Yamasa Corporation Medicinal compositions for treating eye diseases
JP2002518510A (en) * 1998-06-23 2002-06-25 グラクソ グループ リミテッド 2- (purine-9-yl) -tetrahydrofuran-3,4-diol derivative
JP2003506461A (en) * 1999-06-22 2003-02-18 スィーヴィー セラピューティクス インコーポレイテッド N-pyrazole A2A receptor agonist
JP2004508284A (en) * 2000-02-18 2004-03-18 ファイザー・インク Purine derivatives

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06128281A (en) * 1992-04-24 1994-05-10 Whitby Res Inc Hydrazoadenosines
JP2002518510A (en) * 1998-06-23 2002-06-25 グラクソ グループ リミテッド 2- (purine-9-yl) -tetrahydrofuran-3,4-diol derivative
WO2000012098A1 (en) * 1998-09-01 2000-03-09 Yamasa Corporation Medicinal compositions for treating eye diseases
JP2002173427A (en) * 1998-09-01 2002-06-21 Yamasa Shoyu Co Ltd Medicine composition for treating eye disease
JP2003506461A (en) * 1999-06-22 2003-02-18 スィーヴィー セラピューティクス インコーポレイテッド N-pyrazole A2A receptor agonist
JP2004508284A (en) * 2000-02-18 2004-03-18 ファイザー・インク Purine derivatives

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KONNO T. ET AL.: "Effect of 2-(6-cyano-1-hexyn-1-yl)adenosine on ocular blood flow in rabbits", LIFE SCIENCE, vol. 80, no. 12, February 2007 (2007-02-01), pages 1115 - 1122, XP005891969 *
KONNO T.: "Role of adenosine in intraocular pressure", NIPPON YAKURIGAKU ZASSHI, vol. 123, no. 4, 2004, pages 289 - 294 *
MASAYUKI U. ET AL.: "2-Aralkoxyadenosines: potent and selective agonists at the coronary artery A2 adenosine receptor", J. MED. CHEM., vol. 34, 1991, pages 1340 - 1344, XP002961133, DOI: doi:10.1021/jm00108a015 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010524933A (en) * 2007-04-16 2010-07-22 参天製薬株式会社 Glaucoma therapeutic agent containing an adenosine derivative as an active ingredient

Also Published As

Publication number Publication date
JP2008285478A (en) 2008-11-27

Similar Documents

Publication Publication Date Title
WO2005080384A3 (en) Benzimidazole derivative and use as aii receptor antagonist
WO2005075458A8 (en) Pyrimidine derivatives as orexin receptors antagonists
MX2009013626A (en) 17beta-cyano-18a-homo-19-nor-androst-4-ene derivative, use thereof and medicaments containing said derivative.
WO2008006043A3 (en) 1,3-oxazole derivatives useful as anti-atherosclerotic, anti-dyslipidemic, anti-diabetic and anti-obesity agents
WO2002076950A3 (en) Imidiazole derivatives and their use as agonists selective at alpha 2b or 2b/2c adrenergic receptors
WO2008096829A1 (en) Tricyclic compounds
NO20060154L (en) Imidazolyl derivatives
WO2009072621A1 (en) Substituted dihydroazole compound and pest control agent
MY141559A (en) Triazole derivatives as tachykinin receptor antagonists
ATE388958T1 (en) 4'-C-SUBSTITUTED 2-HALOADENOSINE DERIVATIVES
TW200738667A (en) Preparation method for dioxan-2-ylalkylcarbamate derivatives and intermediate thereof
WO2009035067A1 (en) Glucocorticoid receptor agonists consisting of 1,3,3-tri- methyl-7-phenyl-3,4-dihydro-1h-quinoxalin-2-one derivatives
RS51674B (en) Piperidin-4-yl-pyridazin-3-ylamine derivatives as fast dissociating dopamine 2 receptor antagonists
WO2009038064A1 (en) Heterocyclic derivative having inhibitory activity on type-i 11β-hydroxysteroid dehydrogenase
EP1854789A4 (en) CHINAZOLINE DERIVATIVE WITH TYROSINE KINASE HEMMENDER EFFECT
WO2007017728A3 (en) Novel heterocyclic compounds
WO2009095792A3 (en) Substituted heteroarylamide diazepinopyrimidone derivatives
NO20072753L (en) 3-Ethylidene hydrazino-substituted heterocyclic compounds as thrombopoietin receptor activators
MX2009011076A (en) Therapeutic agent for glaucoma containing adenosine derivative as active ingredient.
WO2007144512A3 (en) Diazeniumdiolate derivatives, method for the preparation thereof, pharmaceutical compositions thereof, and use of same in the fields of hypertension and cardiovascular pathologies
NZ552137A (en) New 4-benzylidene-piperidin derivatives
TW200606152A (en) Piperidine compound and process for preparing the same
WO2008149834A1 (en) Pyrimidodiazepinone derivative
WO2005003087A3 (en) Oxazole derivatives as antibacterial agents
RS20060072A (en) Aminoquinoline derivatives and their use as adenosine a3 ligands

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08740475

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08740475

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP

点击 这是indexloc提供的php浏览器服务,不要输入任何密码和下载